2 research outputs found
Prevalence of Overweight, Obesity and Abdominal Obesity among the Adult Population of Yakutia
This study describes data obtained as a result of a one-stage epidemiological study for levels of CVD risk factors among indigenous and non-indigenous populations of the Republic of Sakha (Yakutia) (RS(Y)).
A total of 1,856 indigenous residents (Yakuts) and non-indigenous residents (Russians) were examined: 512 men (mean age 47.5Β±15.1) and 1,344 women (mean age 48.1Β±14.2). Among the surveyed adult population of Yakutia, the average values of BMI, regardless of ethnicity, were high with a regular increase in this indicator with age, especially in women. Overweight is more common for indigenous men (40%) compared with indigenous women (34.5 %). Among the non-indigenous residents, there were no gender differences. In the sample of the indigenous population, obesity was more common in women (24.3%) than in men (18.7%). Among non-indigenous residents, similar differences were not obtained, except for a higher incidence of obesity in older women. The average waist circumference in men and women of both ethnic groups is not high, but the indicators are higher for men than for women; the gender differences are leveled in the older age group in both ethnic groups. Prevalence of abdominal obesity (AO) is extremely high in indigenous residents (61.6%); in both ethnic groups, the prevalence of AO is higher among women than men. The incidence of overweight, obesity and AO was significantly higher in Yakut people
ΠΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΡΠ΅ ΠΈ ΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΊΠ°Π½Π΄ΠΈΠ΄Π°ΡΠ½ΠΎΠΉ ΠΏΠ΅ΠΏΡΠΈΠ΄Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΡΠΎΡΠΈΠ² SARS-CoV-2
Background. In 2020, the pandemic caused by novel coronavirus infection has become one of the most critical global health challenges during the past century. The lack of a vaccine, as the most effective way to control the novel infection, has prompted the development of a large number of preventive products by the scientific community. We have developed a candidate vaccine (EpiVacCorona) against novel coronavirus infection caused by SARS-CoV-2 that is based on chemically synthesized peptides conjugated to a carrier protein and adsorbed on aluminum hydroxide and studied the specific activity of the developed vaccine.
Aims study of the immunogenicity and protectivity of the peptide candidate vaccine EpiVacCorona.
Methods. The work was performed using standard molecular biological, virological and histological methods.
Results. It was demonstrated that EpiVacCorona, when administered twice, spaced 14 days apart, to hamsters, ferrets, and non-human primates (african green monkeys, rhesus macaques) at a dose of 260 g, which is equal to one inoculation dose for humans, induces virus-specific antibodies in 100% of the animals. Experiments in hamsters showed this vaccine to be associated with the dose-dependent immunogenicity. The vaccine was shown to accelerate the elimination of the virus from the upper respiratory tract in ferrets and prevent the development of pneumonia in hamsters and non-human primates following a respiratory challenge with novel coronavirus.
Conclusions. The results of a preclinical specific activity study indicate that the use of EpiVacCorona has the potential for human vaccination.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. Π 2020 Π³. ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΡ, Π²ΡΠ·Π²Π°Π½Π½Π°Ρ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ, ΡΡΠ°Π»Π° ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΡΠ°ΠΌΡΡ
ΡΠ΅ΡΡΠ΅Π·Π½ΡΡ
ΠΈΡΠΏΡΡΠ°Π½ΠΈΠΉ Π΄Π»Ρ Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ Π·Π° ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π΅ ΡΡΠΎΠ»Π΅ΡΠΈΠ΅. ΠΡΡΡΡΡΡΠ²ΠΈΠ΅ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΊΠ°ΠΊ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π΄Π΅ΠΉΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΏΠΎΡΠΎΠ±Π° Π±ΠΎΡΡΠ±Ρ ΠΏΡΠΎΡΠΈΠ² Π½ΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΎΠ±ΡΡΠ»ΠΎΠ²ΠΈΠ»ΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΡ Π½Π°ΡΡΠ½ΡΠΌ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²ΠΎΠΌ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΠ°ΠΌΠΈ Π±ΡΠ»Π° ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΊΠ°Π½Π΄ΠΈΠ΄Π°ΡΠ½Π°Ρ Π²Π°ΠΊΡΠΈΠ½Π° (ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½Π°) ΠΏΡΠΎΡΠΈΠ² Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ SARS-CoV-2 Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈ ΡΠΈΠ½ΡΠ΅Π·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠ΅ΠΏΡΠΈΠ΄ΠΎΠ², ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° Π±Π΅Π»ΠΎΠΊ-Π½ΠΎΡΠΈΡΠ΅Π»Ρ ΠΈ Π°Π΄ΡΠΎΡΠ±ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠ΄ Π°Π»ΡΠΌΠΈΠ½ΠΈΡ, ΠΈ ΠΈΠ·ΡΡΠ΅Π½Π° Π΅Π΅ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ.
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΡΡ
ΠΈ ΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² ΠΊΠ°Π½Π΄ΠΈΠ΄Π°ΡΠ½ΠΎΠΉ ΠΏΠ΅ΠΏΡΠΈΠ΄Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½Π°.
ΠΠ΅ΡΠΎΠ΄Ρ. Π Π°Π±ΠΎΡΠ° Π±ΡΠ»Π° Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
, Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ².
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½Π° ΠΏΡΠΈ Π΄Π²ΡΠΊΡΠ°ΡΠ½ΠΎΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΠΈ Ρ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠΌ Π² 14 Π΄Π½Π΅ΠΉ Ρ
ΠΎΠΌΡΠΊΠ°ΠΌ, Ρ
ΠΎΡΡΠΊΠ°ΠΌ ΠΈ Π½ΠΈΠ·ΡΠΈΠΌ ΠΏΡΠΈΠΌΠ°ΡΠ°ΠΌ (Π°ΡΡΠΈΠΊΠ°Π½ΡΠΊΠΈΠΌ Π·Π΅Π»Π΅Π½ΡΠΌ ΠΌΠ°ΡΡΡΡΠΊΠ°ΠΌ, ΠΌΠ°ΠΊΠ°ΠΊΠ°ΠΌ-ΡΠ΅Π·ΡΡΠ°ΠΌ) Π² Π΄ΠΎΠ·Π΅ 260 ΠΌΠΊΠ³, ΡΠ°Π²Π½ΠΎΠΉ ΠΎΠ΄Π½ΠΎΠΉ ΠΏΡΠΈΠ²ΠΈΠ²ΠΎΡΠ½ΠΎΠΉ Π΄ΠΎΠ·Π΅ Π΄Π»Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, Π²ΡΠ·ΡΠ²Π°Π΅Ρ ΠΈΠ½Π΄ΡΠΊΡΠΈΡ Π²ΠΈΡΡΡΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» Ρ 100% ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
. Π ΠΎΠΏΡΡΠ°Ρ
Π½Π° Ρ
ΠΎΠΌΡΠΊΠ°Ρ
ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π²Π°ΠΊΡΠΈΠ½Π½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡΡΡ, Π²Π°ΠΊΡΠΈΠ½Π° ΠΈΠ½Π΄ΡΡΠΈΡΡΠ΅Ρ ΡΡΠΊΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠ»ΠΈΠΌΠΈΠ½Π°ΡΠΈΠΈ Π²ΠΈΡΡΡΠ° ΠΈΠ· Π²Π΅ΡΡ
Π½ΠΈΡ
Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ Ρ Ρ
ΠΎΡΡΠΊΠΎΠ² ΠΈ ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΠ°Π΅Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ Ρ Ρ
ΠΎΠΌΡΠΊΠΎΠ² ΠΈ Π½ΠΈΠ·ΡΠΈΡ
ΠΏΡΠΈΠΌΠ°ΡΠΎΠ² ΠΏΠΎΡΠ»Π΅ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π·Π°ΡΠ°ΠΆΠ΅Π½ΠΈΡ Π½ΠΎΠ²ΡΠΌ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠΎΠΌ.
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΄ΠΎΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½Π° Π΄Π»Ρ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π»ΡΠ΄Π΅ΠΉ